US 10851102
Imidazole and triazole containing bicyclic compounds as JAK inhibitors
granted A61KA61K9/0014A61P
Quick answer
US patent 10851102 (Imidazole and triazole containing bicyclic compounds as JAK inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K9/0014, A61P, A61P1/00, A61P17/00